Ingredient suppliers are repositioning collagen peptides around "skin longevity" rather than anti-aging, according to an industry report in Personal Care Insights, which interviewed Gelita, Rousselot and Puredia about what is driving demand. The two forces they name are the spread of GLP-1 weight-loss drugs and younger buyers who want prevention rather than repair.

Collagen peptides are short chains made by hydrolyzing collagen protein, usually taken orally. The suppliers' pitch is that the peptide profile created during hydrolysis, not the gram count on the front of the pack, is what determines biological activity.

The GLP-1 opening

Puredia general manager Michael Yuen told the outlet that about 1 in 8 US adults have used a GLP-1, roughly 31 million people and double the level of spring 2024. He also said two-thirds of US facial plastic surgeons report seeing more rapid-weight-loss patients, with facial fat grafting up about 50% for the second year running.

That is the commercial opening, and the suppliers are not subtle about it. Rousselot's Andrew Ross framed collagen peptides as a protein source for people losing weight quickly, while Gelita's Oliver Wolf drew a line the category will be tempted to cross: a collagen ingredient "should not be presented as a treatment for medication-related effects."

Where the human data stops

The most interesting admission in the piece comes from Ross on GHK-Cu, the copper peptide linked to tissue repair that has become a fixture in topical marketing. Collagen-stimulating peptides like it "make sense from a mechanistic point of view, but still lack substantial human clinical trial data," he said.

He went further on the combination everyone will eventually sell: pairing GHK-Cu with a hydrolyzed collagen peptide could theoretically support ECM remodeling, but "none of those studies have been done." That is a supplier saying the quiet part on the record, and it is worth more than the market projections around it.

Gen Z buys prevention

Yuen said collagen now ranks third among Gen Z wellness priorities, up from sixth in 2023, and that a 25-year-old is buying against UV, pollution, glycation and stress rather than wrinkles. Yuen put nutricosmetics at US$10.29 billion in 2026, growing 8.31% a year through 2031.

Bottom line

Wolf expects separation between generic collagen and precision ingredients with mechanistic data and human outcomes, or as he put it, a move "from ingredient recognition to ingredient accountability." On the newer peptides driving the excitement, by Rousselot's own account that accounting has not started.